Subscribe   RSS Contact Us

Holcombe’s E&C Testimony: PDUFA VI Will Take Patient-focused Drug Development to New Level

March 23, 2017 – In testimony before the House Energy and Commerce Committee’s Subcommittee on Health yesterday, Biotechnology Industry Organization ... read more

Gottlieb Is “Known” Entity to Pharma Industry

March 20, 2017 – Although medical marketers are very familiar with Scott Gottlieb, President Donald Trump’s choice for the top ... read more

Industry Groups Oppose Oregon Bill Calling for Advertising Price Disclosure

March 9, 2017 – Four major advertising and media industry groups have issued a joint letter opposing an Oregon bill ... read more

Trump Needs to Take a Closer Look at FDA Performance

March 8, 2017 – In an open letter to President Donald Trump, Pharmalot’s Ed Silverman asks that before Trump criticizes ... read more

Industry Peacekeeping with President Trump Holds Promise But Portends Danger

By John Kamp, Executive Director, Coalition for Healthcare Communication [Editor’s Note: This “The Final Word” column appeared in the February ... read more

Citizen Petition Calls on FDA to Stay Final Rule Establishing “Totality of the Evidence” Standard for Intended Use

Feb. 24, 2017 – The FDA recently published a final rule on intended use and adequate directions for use that ... read more

Previous Next

Marketing Tax Provision Escapes Senate Vote

Jan. 13, 2017 – An amendment introduced by Sen. Al Franken (D-Minn.) to eliminate the tax deduction for drug marketing costs was not included in this week’s Senate voting on the repeal of the Affordable Care Act, thanks to immediate action by The Advertising Coalition (TAC), which focused on messages to all Senate offices that the provision violated good public policy and the First Amendment.

As a result of TAC’s efforts, “the provision was stricken from the agenda even before the full Senate vote,” according to Coalition for Healthcare Communication Executive Director John Kamp.

Franken’s provision had the purpose of establishing “a deficit-neutral reserve fund relating to unfair tax breaks to drug companies” and called for “disallowing the deduction for direct-to-consumer advertising of prescription drugs” and promotional expenses for prescription drugs.

TAC talking points on the Franken amendment asserted the following:

  • The First Amendment protects the right of pharmaceutical companies to advertise to consumers; Congress and the FDA have established procedures to assure this speech is truthful and balanced.
  • The purpose of DTC advertising is to provide patients with information regarding potential medical conditions or beneficial therapies.
  • The Franken proposal potentially infringes on a company’s right to advertise under the First Amendment.
  • Advertising has been recognized as essential to business and treated as an ordinary and necessary business expense since the Tac Code was adopted.
  • Advertising created millions of jobs and adds trillion of dollars to U.S. economic activity and benefits all levels of our economy. In 2014, advertising supported 20 million U.S. jobs and $5.8 trillion in U.S. sales.

On Jan. 12, Jim Davidson, head of TAC, thanked media and advertising members, saying that the organization is pleased that the amendment was not included in the Senate vote. “We are grateful to our friends who worked to keep it from being added to the list,” Davidson said.